IDEA-033 Open Label Study

NCT00372333 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 491

Last updated 2009-03-20

No results posted yet for this study

Summary

The main aim of the study is to evaluate safety, efficacy, compliance, and usage of epicutaneously applied IDEA-033 in joint / musculoskeletal pain or soft tissue inflammation.

Conditions

Interventions

DRUG

IDEA-033

Sponsors & Collaborators

  • IDEA AG

    lead INDUSTRY

Principal Investigators

  • Ilka Rother · X-pert-med GmbH Munich

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-12-31
Completion
2008-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00372333 on ClinicalTrials.gov